Journal: PLoS Pathogens
Article Title: Reduced IRF4 expression promotes lytic phenotype in Type 2 EBV-infected B cells
doi: 10.1371/journal.ppat.1010453
Figure Lengend Snippet: Immunoblot analyses were performed to compare the protein expression levels of IRF4 (A) or EBF1 and Z (B) in T1 versus T2 LCLs as indicated (using the same cell lysates). Tubulin was used as loading control. The numbers below the IRF4 immunoblot quantify the results using Image Studio Lite software to normalize the level of IRF4 expression to tubulin expression. Results are presented as the ratio of IRF4 expression relative to tubulin, in T2 cells (averaged) relative to T1 cells (averaged). The T1 IRF4 value is set as 1. The transcript expression of IRF4 (as determined by RNA-seq) is also shown for various different Type 1 and Type 2 LCL lines, along with the log2FC fold change in gene expression in T2 versus T1 cell lines, and the adjusted p value.
Article Snippet: The following antibodies were used for immunoblot analyses in this study: anti-R rabbit polyclonal antibody directed against the R peptide (peptide sequence EDPDEETSSQAVKALREMAD), anti-BZLF1 (Santa Cruz #sc-53904), anti-BMRF1 (Millipore #MAB8186), anti-IRF4 (Santa Cruz #sc-56713), anti-EBF1 (Biotechne #AF5165), anti-CD11C (Cell Signaling #45581), anti-caspase 1 (Abclonal #A0964), anti-ENPP2 (Proteintech #14243-1-AP), anti-Runx1 (Cell Signaling #4336S), anti-RUNX3 (Cell Signaling #13089), anti-NFATc1 (Santa Cruz #sc-7294), anti-NFATc2 (Cell Signaling #4389), anti-FYN (Santa Cruz #sc-434), anti-TNFRSF9 (Cell Signaling #34594), anti-CD9 (Cell Signaling #13174), anti-HLA DR/MHC class II (Santa Cruz #sc—53319), anti-AHR (Biotechne #AF6185), anti-CYP1B (Proteintech #18505-1-AP), anti-phospho-ERK (Cell Signaling #9101), anti-Tubulin (Sigma #T5168), anti-actin (Sigma #A5441), anti-V5 (Santa Cruz #sc—58052), and anti LMP2A (Santa Cruz #sc-101314).
Techniques: Western Blot, Expressing, Software, RNA Sequencing Assay